Therapeutic proteins : strategies to modulate their plasma half-lives /

• Άλλοι συγγραφείς: Kontermann, Roland, 1961- (Επιμελητής έκδοσης)
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Weinheim, Germany : Wiley-Blackwell, an imprint of John Wiley & Sons, 2012.
• Θέματα: Protein drugs > Design.; Proteins > Therapeutic use.; Proteins > pharmacokinetics.; Half-Life.; MEDICAL > Pharmacology.; Electronic books.

 For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals. 

 General information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process.